Aspargo Labs ^{Filed Terms, NYSE: AAGO}

Aspargo is a commercial stage specialty pharmaceutical and med-tech company focused on designing, developing and marketing proprietary, oral liquid suspension formulations of leading oral solid dose prescription (Rx) and over-the-counter (OTC) medications dispensed through “smart”, digitally connected, container closure drug delivery systems and associated mobile apps. Our first commercial product, Sildenafil Oral Suspension, indicated for the treatment of erectile dysfunction (ED), is an oral liquid suspension formulation of sildenafil citrate, the active pharmaceutical ingredient contained in VIAGRA®, administered through a metered dose container closure system consisting of a 30 ml bottle and mechanical pump. We market Sildenafil Oral Suspension in Spain under the brand name, BANDOL®, and in Germany and the United Kingdom under the brand name, HEZKUE®. Sildenafil Oral Suspension is approved for sale in multiple countries in the European Union (EU) and is undergoing the approval process in the United States. Our core business strategy is to develop and promote new uses for our licensed and self-developed technology and know-how, which make it possible to reformulate oral solid dose medications for administration as oral liquid suspensions, and to design and manufacture novel, proprietary, digitally connected, electronic drug delivery devices and associated mobile apps for administration of our proprietary oral suspension formulations to enhance patient centric care and medication adherence.